IM Cannabis exits Germany via disposal to vehicle of its own chief executive
The cannabis company has offloaded Adjupharm and two minority holdings to a buyer controlled by Oren Shuster, leaving it as an Israel-only importer and distributor.
IM Cannabis now operates in a single market. Following a disposal that closed on 29 September 2026, the company's business consists of importing and distributing medical cannabis in Israel under an IMCA licence, according to its management discussion and analysis for the nine months to 30 September.
The buyer was Slil.com Holding, which is controlled by chief executive Oren Shuster. It acquired IMC Holdings, the group entity that included the German business run through Adjupharm. The sale also removed the company's interests in Xinteza and Shiran from the group.
The summary of the filing available to CompePharma does not state the price, payment terms or how the board or shareholders considered a sale to an entity tied to the CEO. The commercial effect on revenue and margins therefore cannot be measured from the material reviewed, and the full filing would be needed for that.
In a separate step, IM Cannabis consolidated its shares on 27 August 2026 at a ratio of 30 to 1. The company said the move was meant to bring it back within Nasdaq's listing requirements.
Why it matters
- The group's revenue base now rests on Israeli import and distribution, so its licence position and supply arrangements there matter more than before.
- Partners and suppliers dealing with the former Adjupharm business should confirm who owns and runs it following the transfer out of the group.
- With the CEO's own entity as buyer and no price disclosed in the available summary, the full MD&A is the place to look for terms and governance detail.
Company's press release (SEC filing): IM Cannabis Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
Quantum Biopharma narrows nine-month net loss to $17.3M as cash and digital assets rise
Candel delays prostate cancer BLA to mid-2027 as it refines assay with FDA
Auditor flags going-concern doubt at Marea and M2 despite $75.3M cash
